The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice

Aims/hypothesis Second-generation antipsychotic (SGA) drugs have been associated with the development of type 2 diabetes and the metabolic syndrome in patients with schizophrenia. In this study, we aimed to investigate the effects of two different SGA drugs, olanzapine and aripiprazole, on metabolic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetologia 2022-03, Vol.65 (3), p.490-505
Hauptverfasser:	Grajales, Diana, Vázquez, Patricia, Ruíz-Rosario, Mónica, Tudurí, Eva, Mirasierra, Mercedes, Ferreira, Vítor, Hitos, Ana B., Koller, Dora, Zubiaur, Pablo, Cigudosa, Juan C., Abad-Santos, Francisco, Vallejo, Mario, Quesada, Iván, Tirosh, Boaz, Leibowitz, Gil, Valverde, Ángela M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antipsychotic Agents - adverse effects Antipsychotics Aripiprazole Aripiprazole - metabolism Aripiprazole - pharmacology Beta cells Body weight gain Calcium imaging Calorimetry Cell size Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - metabolism Diet Drug development Female Glucose Glucose tolerance Human Physiology Humans Immunofluorescence Insulin Insulin secretion Internal Medicine Intolerance Islets of Langerhans - metabolism Medicine Medicine & Public Health Mental disorders Metabolic Diseases Metabolic syndrome Mice Olanzapine Olanzapine - adverse effects Olanzapine - metabolism Patients Psychotropic drugs Rapamycin Schizophrenia TOR protein Transcriptomics Tryptophan Tryptophan hydroxylase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!